Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Open-label Clinical Trial to Evaluate the Objective Response Rate of Bevacizumab in Combination With Modified FOLFOX-6 Followed by One Year of Maintenance With Bevacizumab Alone in Patients With Initially Not or Borderline Resectable Colorectal Liver Metastases (The CLMO-001 Trial)

Next Previous
Trial Profile

A Multi-center, Open-label Clinical Trial to Evaluate the Objective Response Rate of Bevacizumab in Combination With Modified FOLFOX-6 Followed by One Year of Maintenance With Bevacizumab Alone in Patients With Initially Not or Borderline Resectable Colorectal Liver Metastases (The CLMO-001 Trial)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jun 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Fluorouracil; Levofolinic acid; Oxaliplatin
  • Indications Colon cancer; Liver metastases; Rectal cancer
  • Focus Therapeutic Use
  • Acronyms ABOVE
  • Sponsors Roche

Most Recent Events

  • 22 Jul 2016 Status changed from active, no longer recruiting to completed.
  • 07 Oct 2015 Planned End Date changed from 1 Jun 2016 to 1 Oct 2016 as reported by ClinicalTrials.gov record.
  • 19 May 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Jan 2017 to 1 Jun 2016.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top